LONG-TERM TOLERANCE OF PERINDOPRIL IN HYPERTENSIVE PATIENTS WITH IMPAIRED RENAL-FUNCTION

被引:3
作者
DRATWA, M
SENNESAEL, J
TAILLARD, F
BAGUET, F
SUC, JM
LINS, RL
LAMEIRE, N
机构
[1] VRIJE UNIV BRUSSELS,AKAD ZIEKENHUIS,NEFROL EENHEID,B-1050 BRUSSELS,BELGIUM
[2] HOP ST JACQUES,CLERMONT FERRAND,FRANCE
[3] CHU TOULOUSE RANGUEIL,SERV NEPHROL,TOULOUSE,FRANCE
[4] HOP UNIV BRUGMANN,UNITE HEMODIALYSE,B-1020 BRUSSELS,BELGIUM
[5] IRIS CO & DEV,COURBEVOIE,FRANCE
[6] AKAD ZIEKENHUIS STUYVENBERG,DIENST NIERZIEKTEN,ANTWERP,BELGIUM
[7] STATE UNIV GHENT,UNIV ZIEKENHUIS GENT,DIENST NIERZIEKTEN,B-9000 GHENT,BELGIUM
关键词
ACE INHIBITOR; PERINDOPRIL; RENAL FAILURE; HYPERTENSION;
D O I
10.1097/00005344-199100180-00009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thirty-six hypertensive patients with impaired renal function entered a long-term study to assess the safety of perindopril. There were 28 men and 8 women of mean age 57.1 +/- 2.0 years (mean +/- SEM). The duration of documented hypertension was 7.3 +/- 1.2 years. Perindopril was given orally in single daily doses. The initial dosage was chosen according to the degree of renal function impairment: 29 patients received 4 mg o.d. [creatinine clearance (Cl(cr)), 42.2 +/- 3.2 ml.min-1] and 7 patients received 2 mg o.d. (Cl(cr) 22.3 +/- 3.1 ml.min-1). Patients in whom blood pressure was not controlled had their dose doubled and then, if necessary, an additional diuretic therapy was added at subsequent visits. Six patients were withdrawn for adverse events (myocardial infarction, pneumonia, leucopenia in a patient who had lupus, diabetes mellitus, skin rash, epigastric pain), two patients were withdrawn for poor compliance, and three for personal convenience. The mean duration of treatment was 10.2 months with a range of 3-12 months (excluding one patient who died from myocardial infarction in the first days of the study and was not included in the analysis). Systolic and diastolic blood pressure decreased significantly (from 170.5/100.6 +/- 3.4/1.8 mm Hg to 151.8/88.8 +/- 3.0/1.7 mm Hg, n = 35, p < 0.001). Baseline and final values of plasma creatinine (from 223.7 +/- 22.7 to 234.7 +/- 28.5-mu-mol/l), Cl(cr) (42.5 +/- 3.2 to 45.7 +/- 4.6 ml.min-1), and kalemia (from 4.4 +/- 0.1 to 4.7 +/- 0.1 mmol/L) were not statistically different. Proteinuria decreased significantly (from 1.88 +/- O.56 to 0.86 +/- 0.23 g/24 h; p < 0.01). Only minor side effects were recorded. In this study perindopril was shown to be efficient and well tolerated in hypertensive patients with renal failure.
引用
收藏
页码:S40 / S44
页数:5
相关论文
共 9 条
[1]  
GRIFFING GT, 1982, LANCET, V1, P1361
[2]   REDUCTION OF PROTEINURIA BY ANGIOTENSIN CONVERTING ENZYME-INHIBITION [J].
HEEG, JE ;
DEJONG, PE ;
VANDERHEM, GK ;
DEZEEUW, D .
KIDNEY INTERNATIONAL, 1987, 32 (01) :78-83
[3]  
MANN JFE, 1990, NEPHRON, V55, P38
[4]  
OPSAHL JA, 1990, DRUGS S2, V39, P22
[5]  
RAIJ L, 1989, J HYPERTENS S7, V7, P533
[6]  
SANTONI JP, 1989, CLIN EXP HYPERTENS A, V11, P605
[7]   SINGLE DOSE PHARMACOKINETICS OF PERINDOPRIL AND ITS METABOLITES IN HYPERTENSIVE PATIENTS WITH VARIOUS DEGREES OF RENAL-INSUFFICIENCY [J].
VERPOOTEN, GA ;
GENISSEL, PM ;
THOMAS, JR ;
DEBROE, ME .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (02) :187-192
[8]  
WILLIAMS GH, 1988, NEW ENGL J MED, V319, P1517
[9]  
ZANCHETTI A, 1989, CLIN EXP HYPERTENS A, V11, P555